Technical Analysis for CATB - Catabasis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 6.08 0.50% 0.03
CATB closed up 0.5 percent on Friday, August 16, 2019, on 50 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical CATB trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness 0.50%
Below Lower BB Weakness 0.50%
Lower Bollinger Band Touch Weakness 0.50%
Oversold Stochastic Weakness 0.50%
Below Lower BB Weakness -0.33%
Lower Bollinger Band Touch Weakness -0.33%

Older signals for CATB ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Catabasis Pharmaceuticals, Inc. (Catabasis) is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics based on its safely metabolized and rationally targeted (SMART) linker technology platform. Its SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating various biological targets in one or more related disease pathways. Catabasis engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of its SMART linkers. Catabasis is also engaged in developing other product candidates for the treatment of lipid disorders. The Company's product development pipeline includes three clinical-stage product candidates, namely, CAT-1004, CAT-2000 series, including CAT-2054 and CAT-2003, and CAT-4001, and various programs in preclinical development.
Biopharmaceutical Diseases Lipid Disorders Cat
Is CATB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.76
52 Week Low 3.6
Average Volume 56,312
200-Day Moving Average 6.5378
50-Day Moving Average 6.955
20-Day Moving Average 6.7155
10-Day Moving Average 6.3995
Average True Range 0.3055
ADX 25.33
+DI 10.7375
-DI 29.2031
Chandelier Exit (Long, 3 ATRs ) 6.5935
Chandelier Exit (Short, 3 ATRs ) 6.7865
Upper Bollinger Band 7.4683
Lower Bollinger Band 5.9627
Percent B (%b) 0.08
BandWidth 22.419775
MACD Line -0.2831
MACD Signal Line -0.2073
MACD Histogram -0.0758
Fundamentals Value
Market Cap 136.69 Million
Num Shares 22.5 Million
EPS -1.71
Price-to-Earnings (P/E) Ratio -3.56
Price-to-Sales 0.00
Price-to-Book 2.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.29
Resistance 3 (R3) 6.29 6.23 6.26
Resistance 2 (R2) 6.23 6.17 6.23 6.24
Resistance 1 (R1) 6.15 6.14 6.12 6.15 6.23
Pivot Point 6.09 6.09 6.07 6.09 6.09
Support 1 (S1) 6.01 6.03 5.98 6.01 5.93
Support 2 (S2) 5.95 6.00 5.95 5.92
Support 3 (S3) 5.87 5.95 5.91
Support 4 (S4) 5.87